Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-24T07:29:38.116Z Has data issue: false hasContentIssue false
  • English
  • Français

Potential Role of Active Surveillance in the Control of a Hospital-Wide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae Infection

Published online by Cambridge University Press:  02 January 2015

Debby Ben-David ,
Yasmin Maor ,
Nathan Keller ,
Gili Regev-Yochay ,
Ilana Tal ,
Dalit Shachar ,
Amir Zlotkin ,
Gill Smollan  and
Galia Rahav
Debby Ben-David*
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Yasmin Maor
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Nathan Keller
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Gili Regev-Yochay
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Ilana Tal
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Dalit Shachar
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Amir Zlotkin
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Gill Smollan
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
Galia Rahav
Affiliation:
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer, Israel
*
Infectious Diseases Unit, Sheba Medical Center, Tel Hashomer 52621, Israel (Debby.BenDavid@ sheba.health.gov.il)
Get access Rights & Permissions [Opens in a new window]

Extract

Background.

The recent emergence of carbapenem resistance among Enterobacteriaceae is a major threat for hospitalized patients, and effective strategies are needed.

Objective.

To assess the effect of an intensified intervention, which included active surveillance, on the incidence of infection with carbapenem-resistant Klebsiella pneumoniae.

Setting.

Sheba Medical Center, a 1,600-bed tertiary care teaching hospital in Tel Hashomer, Israel.

Design.

Quasi-experimental study.

Methods.

The medical records of all the patients who acquired a carbapenem-resistant K. pneumoniae infection during 2006 were reviewed. An intensified intervention was initiated in May 2007. In addition to contact precautions, active surveillance was initiated in high-risk units. The incidence of clinical carbapenem-resistant K. pneumoniae infection over time was measured, and interrupted time-series analysis was performed.

Results.

The incidence of clinical carbapenem-resistant K. pneumoniae infection increased 6.42-fold from the first quarter of 2006 up to the initiation of the intervention. In 2006, of the 120 patients whose clinical microbiologic culture results were positive for carbapenem-resistant K. pneumoniae, 67 (56%) developed a nosocomial infection. During the intervention period, the rate of carbapenem-resistant K. pneumoniae rectal colonization was 9%. Of the 390 patients with carbapenem-resistant K. pneumoniae colonization or infection, 204 (52%) were identified by screening cultures. There were a total of 12,391 days of contact precautions, and of these, 4,713 (38%) were added as a result of active surveillance. After initiation of infection control measures, we observed a significant decrease in the incidence of carbapenem-resistant K. pneumoniae infection.

Conclusions.

The use of active surveillance and contact precautions, as part of a multifactorial intervention, may be an effective strategy to decrease rates of nosocomial transmission of carbapenem-resistant K. pneumoniae colonization or infection.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue 6 , June 2010 , pp. 620 - 626
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Yigit, H, Queenan, AM, Anderson, GJ, et al.Novel carbapenem-hydro-lyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151–1161.Google Scholar
2.Bradford, PA, Bratu, S, Urban, C, et al.Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004;39:55–60.CrossRefGoogle Scholar
3.Samra, Z, Ofir, O, Lishtzinsky, Y, Madar-Shapiro, L, Bishara, J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007;30:525–529.CrossRefGoogle Scholar
4.Bratu, S, Landman, D, Haag, R, et al.Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430–1435.Google Scholar
5.Maltezou, HC, Giakkoupi, P, Maragos, A, et al.Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009;58:213–219.CrossRefGoogle Scholar
6.Navon-Venezia, S, Leavitt, A, Schwaber, MJ, et al; Israeli KPC Kpn Study Group. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818–820.CrossRefGoogle ScholarPubMed
7.Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099–1106.Google Scholar
8.Marchaim, D, Navon-Venezia, S, Schwaber, MJ, Carmeli, Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbape-nemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008;52:1413–1418.CrossRefGoogle Scholar
9.Kochar, S, Sheard, T, Sharma, R, et al.Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009;30:447–452.Google Scholar
10.Leavitt, A, Navon-Venezia, S, Chmelnitsky, I, Schwaber, MJ, Carmeli, Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:3026–3029.CrossRefGoogle Scholar
11.Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.CrossRefGoogle ScholarPubMed
12.Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 16th informational supplement. CLSI document M100-S16. Wayne, PA: CLSI, 2006.Google Scholar
13.Woodford, N, Tierno, PM Jr, Young, K, et al.Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004;48: 4793–4799.Google Scholar
14.Hindiyeh, M, Smollen, G, Grossman, Z, et al.Rapid detection of blaKPC carbapenemase genes by real-time PCR. J Clin Microbiol 2008;46:2879–2883.CrossRefGoogle ScholarPubMed
15.Shardell, M, Harris, AD, El-Kamary, SS, Furano, JP, Miller, RR, Perencevich, EN. Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies. Clin Infect Dis 2007;45:901–907.Google Scholar
16.Harbarth, S, Samore, MH. Interventions to control MRSA: high time for time-series analysis? J Antimicrob Chemother 2008;62:431–433.Google Scholar
17.Peña, C, Pujol, M, Ricart, A, et al.Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997;35:9–16.CrossRefGoogle ScholarPubMed
18.Lucet, JC, Chevret, S, Decre, D, et al.Outbreak of multiply resistant en-terobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996;22:430–436.Google Scholar
19.Martins, IS, Pessoa-Silva, CL, Nouer, SA, et al.Endemie extended-spectrum β-lactamase-producing Klebsiella pneumoniae at an intensive care unit: risk factors for colonization and infection. Microb Drug Resist 2006; 12:50–58.Google Scholar
20.Branger, C, Bruneau, B, Lesimple, AL, et al.Epidemiological typing of extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates responsible for five outbreaks in a university hospital. J Hosp Infect 1997;36:23–36.CrossRefGoogle ScholarPubMed
21.DiPersio, JR, Deshpande, LM, Biedenbach, DJ, Toleman, MA, Walsh, TR, Jones, RN. Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis 2005;51:1–7.Google Scholar
22.Kang, CI, Kim, SH, Kim, DM, et al.Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase- producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004;25: 860–867.CrossRefGoogle ScholarPubMed
23.Laurent, C, Rodriguez-Villalobos, H, Rost, F, et al.Intensive care unit outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control measures. Infect Control Hosp Epidemiol 2008;29:517–524.CrossRefGoogle ScholarPubMed
24.Peña, C, Pujol, M, Ardanuy, C, et al.Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998;42:53–58.CrossRefGoogle ScholarPubMed
25.Lee, J, Pai, H, Kim, YK, et al.Control of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 2007;60:629–637.CrossRefGoogle Scholar
26.Lucet, JC, Decré, D, Fichelle, A, et al.Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis 1999;29:1411–1418.CrossRefGoogle ScholarPubMed
27.Harris, AD, McGregor, JC, Furano, JP. What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria? Clin Infect Dis 2006;43(suppl 2):S57–S61.Google Scholar
28.Clancy, M, Graepler, A, Wilson, M, Douglas, I, Johnson, J, Price, CS. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006;27:1009–1017.Google Scholar
29.Jernigan, JA, Clemence, MA, Stott, GA, et al.Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 1995;16:686–696.Google Scholar
30.West, TE, Guerry, C, Hiott, M, Morrow, N, Ward, K, Saigado, CD. Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect Control Hosp Epidemiol 2006;27:233–238.CrossRefGoogle Scholar
31.Troche, G, Joly, LM, Guibert, M, Zazzo, JF. Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 2005;26:161–165.CrossRefGoogle Scholar
32.Gardam, MA, Burrows, LL, Kus, JV, et al.Is surveillance for multidrug-resistant Enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis 2002;186:1754–1760.CrossRefGoogle ScholarPubMed
33.Calfee, D, Jenkins, SG. Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol 2008;29:966–968.Google Scholar
34.Harris, AD, Nemoy, L, Johnson, JA, et al.Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 2004;25: 105–108.CrossRefGoogle ScholarPubMed
35.Chaix, C, Durand-Zaleski, I, Alberti, C, Brun-Buisson, C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745–1751.Google Scholar
36.Harbarth, S, Fankhauser, C, Schrenzel, J, et al.Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008;299:1149–1157.Google Scholar
37.Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256–260.Google Scholar